Stocktoria
Clearside Biomedical, Inc. CLSDQ
OTC · stock · Pharmaceutical Preparations · website · IPO 2016-06-02
Clearside Biomedical, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $8.2M | $1.3M | $29.6M | $7.9M | $2.2M | $30,000 | $345,000 | — | $520,000 |
| R&D expense | $18.6M | $20.8M | $19.6M | $18.5M | $15.1M | $15.7M | $68.3M | $49.1M | — | $19.5M |
| Operating income | -$28.9M | -$24.8M | -$30.3M | -$627,000 | -$17.9M | -$30.3M | -$82.9M | -$58.4M | — | -$25.2M |
| Net income | -$34.4M | -$32.5M | -$32.9M | $376,000 | -$18.2M | -$30.8M | -$82.8M | -$59.0M | — | -$25.9M |
| EPS (diluted) | $-0.47 | $-0.53 | $-0.55 | $0.01 | $-0.39 | $-0.81 | — | — | — | — |
| Operating cash flow | -$24.7M | -$18.1M | -$13.4M | -$10.7M | -$13.1M | -$27.1M | -$79.2M | -$51.1M | $66.8M | -$22.7M |
| Free cash flow | -$25.7M | -$19.9M | -$13.6M | -$10.7M | -$13.2M | -$27.1M | -$79.3M | -$51.4M | — | -$22.7M |
| Cash & equivalents | $20.0M | $28.9M | $48.3M | $30.4M | $17.3M | $22.6M | $8.0M | $9.2M | $23.0M | $34.8M |
| Total assets | $25.1M | $34.0M | $51.3M | $42.9M | $19.3M | $26.8M | $44.1M | $40.5M | $82.0M | $84.8M |
| Total liabilities | $64.0M | $49.9M | $40.7M | $4.9M | $10.6M | $15.6M | $20.5M | $19.1M | $14.8M | $13.2M |
| Shareholders' equity | -$38.9M | -$15.9M | $10.6M | $38.0M | $8.8M | $11.2M | $23.6M | $21.4M | $67.2M | $71.7M |
Growth · year-over-year · Revenue CAGR 15.6%
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -79.8% | +519.9% | -95.5% | +274.7% | +263.3% | +7143.3% | -91.3% | — | — | — |
| Net income growth | — | — | -8862.5% | — | — | — | — | — | — | — |
| EPS growth | — | — | -5600.0% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001539029 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.